• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14

    8/7/24 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email

    GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

    Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's Investor website.

    REGISTER HERE: https://www.renmarkfinancial.com/events/second-quarter-2024-results-virtual-conference-call-nasdaq-prph-l4Vthap3cH

    • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

    About ProPhase Labs

    ProPhase Labs Inc. (NASDAQ:PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.

    For more information, visit www.ProPhaseLabs.com.

    ProPhase Media Relations and Institutional Investor Contact:

    ProPhase Labs, Inc.

    267-880-1111

    [email protected]

    ProPhase Retail Investor Relations Contact:

    Renmark Financial Communications

    John Boidman

    514-939-3989

    [email protected]



    Primary Logo

    Get the next $PRPH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

      1/14/22 6:36:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

      12/20/21 6:25:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase downgraded by Dawson James

      Dawson James downgraded ProPhase from Buy to Neutral

      10/13/21 10:48:44 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:15:08 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hollenshead Stuart

      3 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:00:11 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gleckel Louis Md

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/18/25 5:00:13 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    SEC Filings

    See more
    • SEC Form D filed by ProPhase Labs Inc.

      D - ProPhase Labs, Inc. (0000868278) (Filer)

      7/7/25 9:04:47 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      7/1/25 9:00:30 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: ProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K/A - ProPhase Labs, Inc. (0000868278) (Filer)

      6/27/25 9:00:17 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

      GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

      2/18/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Unveils Project ZenQ-AI

      Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

      4/16/24 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

      UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company me

      6/26/25 7:30:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

      BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology. UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart™ molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart™ achieved greater than a 95% t

      6/17/25 7:30:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Financials

    Live finance-specific insights

    See more
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

      GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register usin

      3/27/25 8:27:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      3/19/24 4:18:00 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/5/23 4:37:55 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/4/23 4:25:33 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care